GlaxoSmithKline PLC — Regulatory Filings 2021

Feb 16, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2021

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc (the ' Company ')

Vesting of Performance Share Plan Awards

This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADSs') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in 2018 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions. Awards were made in 2018 and the three-year performance period commenced on 1 January 2018 and ended on 31 December 2020. The vested shares for the Executive Directors are now subject to an additional two-year vesting period.

The performance measure vesting details for those PDMRs who received awards in 2018 are set out in the following table.

| Portion
of the Award | Measure
and Outcome | Outcome
and Vesting Level — % of
maximum | % of
award |
| --- | --- | --- | --- |
| 1/3rd | Adjusted Free Cash Flow - For the three-year period,
the Company achieved Adjusted Free Cash Flow calculated in
accordance with the principles for the measure of £15.64bn,
which is above the level of £12.60bn required for maximum
vesting. Adjustments
to the original target and vesting schedule were communicated in
the 2019 Annual Report. | 100 | 33.333 |
| 1/3rd | Total Shareholder Return - For the three years ending
31 December 2020, the Company's Total Shareholder Return ranked
9th, which is below the threshold vesting level against a
comparator group of 10 global pharmaceutical companies including
GSK. | 0 | 0 |
| 1/3rd | R&D New Products - For the three-year period, the
Company achieved New Product sales calculated in accordance with
the principles for the measure of £7.337bn, which is above the
level of £4.387bn required for maximum vesting. The
threshold vesting level was £3.589bn. | 100 | 33.333 |
| | Total vesting for 2018 award Lapsed | | 66.666% 33.334% |

The notifications that follow are for awards made to PDMRs and their PCAs and detail the PSP conditional awards that vested, including dividends accrued, on 11 February 2021. The balance of the award made to each PDMR and PCA has lapsed.

The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on the vesting date were £12.552 and $35.52.

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms E Walmsley | |
| --- | --- | --- | --- |
| b) | Position/status | Chief
Executive Officer | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary Shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 340,753 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Dr H Barron | |
| --- | --- | --- | --- |
| b) | Position/status | Chief
Scientific Officer and President, R&D | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | The number of ADSs vesting on awards granted in 2018 under the
Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $0.00 | 180,833 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr R Connor | |
| --- | --- | --- | --- |
| b) | Position/status | President, Global Vaccines | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary Shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 135,107 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms D Conrad | |
| --- | --- | --- | --- |
| b) | Position/status | SVP,
Human Resources | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 9,181 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr J Ford | |
| --- | --- | --- | --- |
| b) | Position/status | SVP
& General Counsel | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | The number of ADSs vesting on awards granted in 2018 under the
Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $0.00 | 5,229 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr N Hirons | |
| --- | --- | --- | --- |
| b) | Position/status | SVP,
Global Ethics and Compliance | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 50,108 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms S Jackson | |
| --- | --- | --- | --- |
| b) | Position/status | SVP,
Global Communications & CEO Office | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 9,181 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D Jackson | |
| --- | --- | --- | --- |
| b) | Position/status | PCA
of Ms S Jackson (SVP,
Global Communications & CEO Office) | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 4,335 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr B McNamara | |
| --- | --- | --- | --- |
| b) | Position/status | CEO,
GSK Consumer Healthcare | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | The number of ADSs vesting on awards granted in 2018 under the
Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $0.00 | 84,162 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr L Miels | |
| --- | --- | --- | --- |
| b) | Position/status | President,
Global Pharmaceuticals | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 175,482 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D Redfern | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Strategy Officer | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 92,622 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr R Simard | |
| --- | --- | --- | --- |
| b) | Position/status | President,
Pharmaceuticals Supply Chain | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 9,181 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms K Terrell | |
| --- | --- | --- | --- |
| b) | Position/status | Chief
Digital & Technology Officer | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | The number of ADSs vesting on awards granted in 2018 under the
Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $0.00 | 69,781 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr P Thomson | |
| --- | --- | --- | --- |
| b) | Position/status | President,
Global Affairs | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 66,043 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms D Waterhouse | |
| --- | --- | --- | --- |
| b) | Position/status | CEO, ViiV Healthcare | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 12,589 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms V Whyte | |
| --- | --- | --- | --- |
| b) | Position/status | Company
Secretary | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The number of Ordinary Shares vesting on awards granted in 2018
under the Company's 2017 Performance Share Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 9,181 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-11 | |
| f) | Place
of the transaction | N/A | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: February
15, 2021
By:/s/ VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break